MX358636B - Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. - Google Patents
Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.Info
- Publication number
- MX358636B MX358636B MX2012008300A MX2012008300A MX358636B MX 358636 B MX358636 B MX 358636B MX 2012008300 A MX2012008300 A MX 2012008300A MX 2012008300 A MX2012008300 A MX 2012008300A MX 358636 B MX358636 B MX 358636B
- Authority
- MX
- Mexico
- Prior art keywords
- nsaid
- naproxen
- concentration
- soft gel
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2690488A CA2690488C (en) | 2010-01-19 | 2010-01-19 | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| PCT/CA2011/000059 WO2011088553A1 (en) | 2010-01-19 | 2011-01-19 | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012008300A MX2012008300A (es) | 2012-11-23 |
| MX358636B true MX358636B (es) | 2018-08-29 |
Family
ID=44303618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008300A MX358636B (es) | 2010-01-19 | 2011-01-19 | Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9480667B2 (OSRAM) |
| EP (2) | EP2525789B1 (OSRAM) |
| JP (2) | JP5975884B2 (OSRAM) |
| AU (1) | AU2011207061B2 (OSRAM) |
| CA (1) | CA2690488C (OSRAM) |
| DK (1) | DK2525789T3 (OSRAM) |
| ES (1) | ES2880813T3 (OSRAM) |
| HU (1) | HUE055771T2 (OSRAM) |
| MX (1) | MX358636B (OSRAM) |
| PL (1) | PL2525789T3 (OSRAM) |
| PT (1) | PT2525789T (OSRAM) |
| SI (1) | SI2525789T1 (OSRAM) |
| WO (1) | WO2011088553A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| JP2017516823A (ja) * | 2014-06-04 | 2017-06-22 | ディグニティ サイエンシス リミテッド | Ｄｇｌａを含む薬学的組成物及びその使用 |
| CN104083339A (zh) * | 2014-08-04 | 2014-10-08 | 人福普克药业（武汉）有限公司 | 萘普生钠软胶囊及其制备方法 |
| US10368284B2 (en) * | 2014-11-12 | 2019-07-30 | T-Mobile Usa, Inc. | Quality of experience-based handover management |
| WO2016181221A1 (en) | 2015-05-13 | 2016-11-17 | Dignity Sciences Limited | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
| JP2018520197A (ja) | 2015-07-21 | 2018-07-26 | アフィミューン リミテッド | 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物 |
| CA3008774C (en) | 2015-12-18 | 2021-10-12 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| US11911517B2 (en) | 2018-05-16 | 2024-02-27 | Bayer Healthcare Llc | High concentration suspension formulation for cold and flu soft gel capsule medications |
| CN109692127A (zh) * | 2019-03-15 | 2019-04-30 | 王征 | 一种密封小胶囊的制备方法 |
| CN113950324A (zh) * | 2019-04-26 | 2022-01-18 | R.P.谢勒技术有限公司 | 微型软胶囊萘普生组合物 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US20220233452A1 (en) * | 2021-01-25 | 2022-07-28 | R.P. Scherer Technologies, Llc | Mini softgel naproxen composition |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
| US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
| CN1130354A (zh) | 1993-09-07 | 1996-09-04 | 普罗克特和廿保尔公司 | 含有丙酸类非甾体消炎药氨基酸盐和减充血药、祛痰药、抗组胺药和镇咳药中至少一种的组合物 |
| US5484606A (en) * | 1994-01-24 | 1996-01-16 | The Procter & Gamble Company | Process for reducing the precipitation of difficulty soluble pharmaceutical actives |
| SK96196A3 (en) * | 1994-01-24 | 1997-03-05 | Procter & Gamble | Process for solubilizing difficultly soluble pharmaceutical actives |
| US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
| CA2318128C (en) * | 1998-01-20 | 2008-10-14 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| US6383515B2 (en) * | 1999-05-28 | 2002-05-07 | Sawyer Maryjean | Solvent system for enhancing solubility |
| US6387400B1 (en) | 2000-08-29 | 2002-05-14 | R.P. Scherer Technologies, Inc. | Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
| WO2004071490A1 (en) * | 2003-02-12 | 2004-08-26 | R & P Korea Co., Ltd. | Solvent system of hardly soluble drug with improved elution rate |
| US20090318558A1 (en) * | 2003-02-12 | 2009-12-24 | Jae-Hwan Kim | Solvent system of hardly soluble drug with improved dissolution rate |
| US20070053868A1 (en) * | 2005-03-08 | 2007-03-08 | Banner Pharmacaps, Inc. | Solvent system for enhancing the solubility of pharmaceutical agents |
| US7582679B2 (en) | 2006-02-03 | 2009-09-01 | Pharmaceutics International Incorporated | Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates |
| US20080014274A1 (en) * | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
| US20110052679A1 (en) * | 2009-08-25 | 2011-03-03 | Pharmaceutics International, Inc. | Solid naproxen concentrates and related dosage forms |
-
2010
- 2010-01-19 CA CA2690488A patent/CA2690488C/en active Active
-
2011
- 2011-01-19 ES ES11734283T patent/ES2880813T3/es active Active
- 2011-01-19 PL PL11734283T patent/PL2525789T3/pl unknown
- 2011-01-19 EP EP11734283.2A patent/EP2525789B1/en active Active
- 2011-01-19 AU AU2011207061A patent/AU2011207061B2/en active Active
- 2011-01-19 PT PT117342832T patent/PT2525789T/pt unknown
- 2011-01-19 HU HUE11734283A patent/HUE055771T2/hu unknown
- 2011-01-19 EP EP21177143.1A patent/EP3909567A1/en active Pending
- 2011-01-19 JP JP2012549215A patent/JP5975884B2/ja active Active
- 2011-01-19 SI SI201131992T patent/SI2525789T1/sl unknown
- 2011-01-19 DK DK11734283.2T patent/DK2525789T3/da active
- 2011-01-19 MX MX2012008300A patent/MX358636B/es active IP Right Grant
- 2011-01-19 US US13/574,159 patent/US9480667B2/en active Active
- 2011-01-19 WO PCT/CA2011/000059 patent/WO2011088553A1/en not_active Ceased
-
2016
- 2016-01-18 JP JP2016007253A patent/JP2016094462A/ja active Pending
- 2016-10-05 US US15/285,968 patent/US10463637B2/en active Active
-
2019
- 2019-09-26 US US16/583,903 patent/US11896566B2/en active Active
-
2023
- 2023-12-29 US US18/400,069 patent/US20240139132A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2525789B1 (en) | 2021-06-02 |
| US20170020832A1 (en) | 2017-01-26 |
| US11896566B2 (en) | 2024-02-13 |
| CA2690488C (en) | 2013-06-11 |
| HUE055771T2 (hu) | 2021-12-28 |
| PT2525789T (pt) | 2021-07-19 |
| JP5975884B2 (ja) | 2016-08-23 |
| EP3909567A1 (en) | 2021-11-17 |
| CA2690488A1 (en) | 2011-07-19 |
| JP2016094462A (ja) | 2016-05-26 |
| AU2011207061B2 (en) | 2015-05-28 |
| DK2525789T3 (da) | 2021-07-19 |
| MX2012008300A (es) | 2012-11-23 |
| US20130011470A1 (en) | 2013-01-10 |
| AU2011207061A1 (en) | 2012-07-26 |
| WO2011088553A1 (en) | 2011-07-28 |
| EP2525789A1 (en) | 2012-11-28 |
| PL2525789T3 (pl) | 2022-01-03 |
| ES2880813T3 (es) | 2021-11-25 |
| EP2525789A4 (en) | 2014-04-30 |
| US20240139132A1 (en) | 2024-05-02 |
| US9480667B2 (en) | 2016-11-01 |
| US20200046662A1 (en) | 2020-02-13 |
| JP2013517304A (ja) | 2013-05-16 |
| SI2525789T1 (sl) | 2021-12-31 |
| US10463637B2 (en) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX358636B (es) | Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. | |
| CY1123023T1 (el) | Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα | |
| CR10728A (es) | Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada | |
| CL2013000218A1 (es) | Forma de dosificacion farmaceutica para administracion oral de una vez al dia, que contiene 6’-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan-1,1’-pirano[3,4,b]indol]-4-amina, para uso en el tratamiento del dolor nocioceptivo. | |
| ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
| MX2019007956A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| CY1123895T1 (el) | Φαρμακευτικα σκευασματα λοραταδινης για εγκλεισμο σε καψακια και συνδυασμοι αυτων | |
| UY31086A1 (es) | Dispositivo dispensador | |
| CO6771406A2 (es) | Una composición combinada | |
| CL2014001828A1 (es) | Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo. | |
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| AR068368A1 (es) | Formas solidas de dosificacion de azitromicina de liberacion controlada | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| EA201390950A1 (ru) | Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой | |
| EA201691034A1 (ru) | Композиции в твердой форме с замедленным высвобождением для перорального введения | |
| MX2016014256A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| CL2013003588A1 (es) | Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa. | |
| AR085431A1 (es) | Complejo de resinato de doxilamina | |
| ECSP16005679A (es) | Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio | |
| EA201491995A1 (ru) | Пероральная лекарственная форма | |
| EA201590732A1 (ru) | Диспергируемая таблетка | |
| PE20151432A1 (es) | Formulaciones de lorazepam de liberacion sostenida | |
| CL2012003685A1 (es) | Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo. | |
| ES2468665B1 (es) | Composición farmacéutica de sulfato de condroitina y celecoxib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |